Combination of the BCL-2 inhibitor ZN-d5 with the WEE1 inhibitor ZN-c3 shows additive or synergistic anti-tumor activity in acute myeloid leukemia (AML) models

被引：0
|
作者：
Izadi, Hooman [1 ]
Hoang, Tiffany [1 ]
Ibrahim, Noah [1 ]
Pinchman, Joseph [1 ]
Boren, Brant C. [1 ]
Ma, Jianhui [1 ]
de Jong, Petrus R. [1 ]
Li, Jiali [1 ]
Bunker, Kevin D. [1 ]
Samatar, Ahmed A. [1 ]
Donate, Fernando [1 ]
机构：
[1] Zentalis, San Diego, CA USA
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2591
引用
收藏
页数：2
相关论文
共 35 条
  • [21] Synergistic Activity of the MCL-1 Inhibitor S63845 with Midostaurin in Preclinical Human Models of FLT3-ITD Mutated Acute Myeloid Leukemia (AML)
    Skwarska, Anna
    Panis, Paul
    Zhang, Qi
    Herbrich, Shelley
    Kurvilla, Vinitha M.
    Baran, Natalia
    Halilovic, Ensar
    Ruvolo, Peter
    Ruvolo, Vivian
    Morris, Erick
    Wei, Andrew
    Moujalled, Donia
    Derreal, Alix
    Banquet, Sebastien
    Andreeff, Michael
    Konopleva, Marina
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S220 - S221
  • [22] BAY 1143572, a first-in-class, highly selective, potent and orally available inhibitor of PTEFb/CDK9 currently in Phase I, shows convincing anti-tumor activity in preclinical models of acute myeloid leukemia (AML)
    Scholz, Arne
    Oellerich, Thomas
    Hussain, Akhtar
    Lindner, Sarah
    Luecking, Ulrich
    Walter, Annette O.
    Ellinghaus, Peter
    Valencia, Ray
    von Nussbaum, Franz
    Mumberg, Dominik
    Brands, Michael
    Ince, Stuart
    Serve, Hubert
    Ziegelbauer, Karl
    CANCER RESEARCH, 2016, 76
  • [23] A Phase 1/2 Multi-Center, Dose-Finding Study to Assess Safety, Tolerability, PK and Efficacy of ZN-d5, a Novel BCL-2 Inhibitor, for Treatment of Subjects with Relapsed/Refractory AL Amyloidosis
    Kastritis, Efstathios
    Matous, Jeffrey, V
    Abro, Emad Uddin
    Eves, P. Taylor
    Zheng, Cheng
    Fiorino, Tony
    Berdeja, Jesus
    BLOOD, 2022, 140 : 4438 - 4439
  • [24] Synergistic Anti-Leukemic Activity with Combination of FLT3 Inhibitor Quizartinib and MDM2 Inhibitor Milademetan in FLT3-ITD Mutant/p53 Wild-Type Acute Myeloid Leukemia Models
    Andreeff, Michael
    Zhang, Weiguo
    Kumar, Prasanna
    Zernovak, Oleg
    Daver, Naval G.
    Isoyama, Takeshi
    Iwanaga, Kouichi
    Togashi, Noriko
    Seki, Takahiko
    BLOOD, 2018, 132
  • [25] Combination of the Chk1 inhibitor (prexasertib) with a PI3K/mTOR inhibitor (LY3023414) induces synergistic anti-tumor activity in triple negative breast cancer (TNBC) models
    Wu, Wenjuan
    Donoho, Greg
    Iversen, Philip
    Dempsey, Jack
    Capen, Andrew
    Castanares, Mark
    Stephens, Jennifer
    Boehnke, Karsten
    Reinhard, Christoph Reinhard
    Lin, Aimee
    CANCER RESEARCH, 2019, 79 (13)
  • [26] Combining IMGN779, a Novel Anti-CD33 Antibody-Drug Conjugate (ADC), with the PARP Inhibitor, Olaparib, Results in Enhanced Anti-Tumor Activity in Preclinical Acute Myeloid Leukemia (AML) Models
    Portwood, Scott
    Puchalski, Robert A.
    Walker, Russell M.
    Wang, Eunice S.
    BLOOD, 2016, 128 (22)
  • [27] The MDM2 inhibitor AMG 232 causes tumor regression and potentiates the anti-tumor activity of MEK inhibition and DNA-damaging cytotoxic agents in preclinical models of acute myeloid leukemia
    Canon, Jude R.
    Osgood, Tao
    Saiki, Anne Y.
    Oliner, Jonathan D.
    CANCER RESEARCH, 2016, 76
  • [28] Correlation of cyclin E1 expression and clinical outcomes in a phase 1b dose-escalation study of azenosertib (ZN-c3), a WEE1 inhibitor, in combination with chemotherapy (CT) in patients (pts) with platinum-resistant or refractory (R/R) epithelial ovarian, peritoneal, or fallopian tube cancer (EOC)
    Liu, Joyce F.
    Fu, Siqing
    Richardson, Gary Edward
    Vranjes, Zivko
    Meniawy, Tarek
    Shannon, Catherine M.
    Hamilton, Erika P.
    Blank, Stephanie V.
    Mathews, Cara Amanda
    Alidzanovic, Jasmina
    Ruseva, Rossitza Krasteva
    Shi, Qing
    Harismendy, Olivier
    Ptaszynski, Ann M.
    Westin, Shannon Neville
    Meric-Bernstam, Funda
    Thaker, Premal H.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [29] FMS-like tyrosine kinase 3 (FLT3) inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor APG-2575 in preclinical models of FLT3-mutant acute myeloid leukemia (AML)
    Fang, Douglas D.
    Zhu, Hengrui
    Tang, Qiuqiong
    Wang, Qixin
    Li, Na
    Fang, Xu
    Min, Ping
    Wang, Guangfeng
    Yang, Dajun
    Zhai, Yifan
    CANCER RESEARCH, 2021, 81 (13)
  • [30] Bcl-2 Inhibitor ABT-199 (GDC-0199) Monotherapy Shows Anti-Tumor Activity Including Complete Remissions In High-Risk Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
    Seymour, John F.
    Davids, Matthew S.
    Pagel, John M.
    Kahl, Brad S.
    Wierda, William G.
    Miller, Thomas P.
    Gerecitano, John F.
    Kipps, Thomas J.
    Anderson, Mary-Ann
    Huang, David C. S.
    Rudersdorf, Nikita K.
    Gressick, Lori A.
    Montalvo, Nicholas P.
    Yang, Panning
    Busman, Todd A.
    Dunbar, Martin
    Cerri, Elisa
    Enschede, Sari H.
    Humerickhouse, Rod A.
    Roberts, Andrew W.
    BLOOD, 2013, 122 (21)
1234